MEDICAGO
7.12.2020 13:32:51 CET | Business Wire | Press release
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today.
Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond to the needs of the global public health community and medical authorities and professionals.
“Taking on this new role with Medicago during this exciting time is a great honour for me,” said Mr. Nagao, President and Chief Executive Officer, Medicago. “I want our employees, investors, and stakeholders such as the Government of Canada to know that I will put all my efforts into seeing our COVID-19 and influenza vaccines through to a successful launch to protect as many people as possible.”
From 2007 to 2017, Mr. Nagao oversaw the establishment of Mitsubishi Tanabe Pharma Corporation’s U.S. presence and led the team that successfully achieved NDA of RADICAVA®, the first FDA-approved drug in over 20 years for the patients with Amyotrophic Lateral Sclerosis (ALS). Prior to that, Mr. Nagao was a Managing Director in investment banking at J.P. Morgan and Deutsche Bank where he was responsible for global clients and leading equity and cross-border M&A transactions in the pharmaceutical and biotechnology sector in North America, Japan and Europe. He has an MBA from Harvard Business School.
Mr. Nagao succeeds Dr. Bruce D. Clark, who held the position of President and CEO of Medicago since 2017 and was instrumental in the development of Medicago’s COVID-19 vaccine candidate.
Medicago recently announced the start of Phase 2/3 clinical trial of its plant-derived VLP vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity, based on the positive Phase 1 results and subsequent allowance to advance to Phase 2/3 by the Canadian regulatory authorities. The company is also building a new facility in Quebec to increase Canada’s domestic capacity for manufacturing vaccines, producing up to a billion doses annually.
“Medicago is at an inflection point. We are moving from a research and development focused organization to become a commercial entity supplying vaccines to Canadians and people around the world,” said Mr. Nagao.
About Medicago
Medicago is a biopharmaceutical company and pioneer in plant-derived therapeutics. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare.
Our mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global healthcare challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide. Our team includes over 450 scientific experts and employees in Canada and the United States and academic affiliations in Europe and South Africa.
Medicago has previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine candidate within one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense. In 2015, Medicago also demonstrated in principle that it could rapidly produce an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
For more information: www.medicago.com
To learn more about our plant-based technology: Video / Website
View source version on businesswire.com: https://www.businesswire.com/news/home/20201204005409/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REJO brings CUBE modular device to Japan in its global premiere16.2.2026 03:00:00 CET | Press release
FlexiCUBE™, the world’s first modular heat-not-burn device, offers adult users customizable color combinations OmniHeat™ 360° technology elevates consistent aerosol performance to new levels Puff Twice feature enables a second heating cycle for auto-heat HNB sticks, allowing adult users access more value from every stick REJO, a pioneering global provider of heat-not-burn (HNB) solutions, today announced the global debut of REJO CUBE, its latest modular HNB device, in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260215596376/en/ REJO CUBE DEVICE-Product Infographic Breaking away from conventional HNB design norms, REJO CUBE introduces a bold new device option featuring a trendy design and dual-mode inhalation experience, launching on Japan’s major e-commerce retail channels from February 16. This launch marks the brand’s latest move following REJO Mate Air’s introduction in Japan in July 2025, when the device’s comp
Sultan bin Ahmed Visits Shanghai Film Studios, Film Park and Stadium15.2.2026 20:24:00 CET | Press release
His Highness Sheikh Sultan bin Ahmed bin Sultan Al Qasimi, Deputy Ruler of Sharjah and Chairman of the Sharjah Media Council, visited the 800,000-square-metre Shanghai Film Studios and Film Park in the town of Shidon in the Chinese city of Shanghai on Saturday. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260215440594/en/ Sultan bin Ahmed visits Shanghai Film Studios, Film Park and Stadium (Photo: AETOSWire) His Highness watched a video outlining the specifications of the Shanghai studios, which comprise 4 professional studios ranging in size from 800 to 3000 square metres, a large costume warehouse, production support facilities, classic cars, and an integrated set of production services. His Highness was briefed on the work produced using artificial intelligence technologies. He toured the sound recording rooms, image quality control, editing and post-production facilities, and listened to an explanation on the developme
Estithmar Holding Establishes “Estithmar Capital” for Financial Investment Management15.2.2026 18:45:00 CET | Press release
Estithmar Holding Q.P.S.C. announced today the establishment of its fifth group, “Estithmar Capital,” in a strategic step aimed at strengthening the company’s expansion and diversifying the sectors in which it operates. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260215458570/en/ Estithmar Holding Establishes “Estithmar Capital” for Financial Investment Management (Photo: AETOSWire) Estithmar Capital will specialize in managing financial investments, strengthening institutional governance, and operating under clear frameworks for compliance, regulation, and risk management, reflecting Estithmar Holding’s vision for sustainability and responsible, well-structured growth. The establishment of Estithmar Capital supports Estithmar Holding’s broader strategy of diversifying financial assets, improving capital efficiency, and unifying governance practices across various markets. Through a centralized and disciplined approach, t
Align Partners Issues Third Public Shareholder Letter and Submits Formal Shareholder Proposals to Coway14.2.2026 12:31:00 CET | Press release
Align Partners highlights Coway’s persistent undervaluation despite steady global growth, citing structural ROE decline as a key driver Align Partners urges the Board to address inefficient capital structure and strengthen shareholder return discipline; requests a formal response by March 13, 2026 The proposals call for stronger Board independence, enhanced Audit Committee oversight, and improved compensation transparency Align Partners Capital Management Inc. (“Align Partners”), a shareholder of Coway Co., Ltd. (“Coway” or the “Company”), has submitted formal shareholder proposals for the Company’s upcoming 37th Annual General Meeting (“AGM”) and issued its third public shareholder letter to Coway’s Board of Directors. Coway is South Korea’s leading home appliance rental platform, supported by a strong global brand and sales network. Since Netmarble became the largest shareholder in 2020, Coway has delivered steady operating growth, with revenue and operating profit increasing at comp
HM King Mohammed VI Presides Over the Launch Ceremony of the Aircraft Landing Gear Production Plant Project, Representing an Investment of €280 million by the Safran Group in Morocco13.2.2026 21:10:00 CET | Press release
His Majesty King Mohammed VI, may God assist Him, accompanied by HRH Crown Prince Moulay El Hassan, chaired on Friday at the Royal Palace in Casablanca the presentation and launch ceremony of the project to build a landing gear production factory for Safran in Nouaceur, a project that reinforces Morocco as a destination of choice and a true integrated industrial actor at the heart of the global economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260213269786/en/ His Majesty King Mohammed VI, accompanied by HRH Crown Prince Moulay El Hassan, chaired on Friday at the Royal Palace in Casablanca the presentation and launch ceremony of the project to build a landing gear production factory for Safran in Nouaceur Considered one of the largest manufacturing centres in the world for Safran Landing Systems, the plant will represent an investment of more than EUR 280 million, create 500 jobs, and operate on 100% decarbonised energ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom